Skip to content

SQ53 Disinfectant Wipes for Prevention of CRBSI

SQ53 Disinfectant Wipes for Prevention of Catheter Related Blood Stream Infection in Patients Receiving Home Parenteral Nutrition: A Single Blind Randomized Placebo-controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04822467
Enrollment
59
Registered
2021-03-30
Start date
2021-12-10
Completion date
2022-12-07
Last updated
2023-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related Bloodstream Infection

Brief summary

SQ53 is a novel antimicrobial, sporicidal solution that is based on a platform of quaternary ammonium chloride compounds. It has been tested against a wide range of bacteria, viruses, spores and fungal pathogens. Extensive laboratory testing has demonstrated the effectiveness of SQ53 impregnated wipes in cleaning surfaces including catheters over a 24 hour plus time period. SQ53 also received an in vitro evaluation of the irritancy potential using a tissue engineered human skin model and was found to have no potential for skin irritation. SQ53 is available as a sterilized pack with a single wipe inside. The pack is easy to open by tearing off the top end and presenting the contents to the operator to remove under sterile conditions. The current study will be a randomized single-blinded placebo-controlled clinical trial for SQ53 wipes intended for catheter cleaning in patients receiving home parenteral nutrition.

Detailed description

Parenteral nutrition (PN) therapy is an essential component of medical management of patients suffering from intestinal failure. Depending on the underlying etiology and the type of intestinal failure, the duration of parenteral nutrition therapy could range from several weeks to several years, although a substantial proportion of these patients also require lifelong parenteral nutrition support. These patients continue the infusion of PN at their homes and are managed by the Cleveland Clinic's Home PN support team. These patients require Central Venous Catheters (CVC) for prolonged period of time for infusion of parenteral nutrition. The two most commonly used central catheters for TPN infusion are the Peripherally Inserted Central Catheter (PICC) and Tunneled CVCs. Catheter related blood stream infection (CRBSI) is a major complication of long-term CVCs. CRBSI is associated with high morbidity, mortality and healthcare cost. Additionally, CRBSI can also lead to an interruption in nutrient delivery, loss of work and productivity, premature vascular access device removal, and poor quality of life. Prevention of CRBSI is an important component of clinical management of patients receiving home PN therapy. Several strategies have been adopted to reduce the incidence of CRBSI. A heparin lock solution was used in the past for many years; however, current nutrition society guidelines recommend normal saline locks instead of heparin locks. Published data has suggested that heparin locks have not proven to have a substantial effect on CRBSI prevention, and it paradoxically increases the infection risk due to biofilm production. Antibiotic locks have also been used, although this practice is largely not preferred due to increased risk of infections with resistant microorganisms. Taurolidine is another lock solution which has been studied in the countries outside the United States such as Canada; however, it has not been approved for the use in the U.S. yet.1

Interventions

DEVICESQ53 Wipe

SQ53-based wipe to be used by the participant daily or upon dressing change

DEVICEEthanol Wipe

Ethanol-based wipe to be used by the participant daily or upon dressing change

Sponsors

JVS Products, Ltd.
CollaboratorUNKNOWN
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients requiring home parenteral nutrition support via PICC line or tunneled CVC.

Exclusion criteria

* Age less than 18 years * Women known to be pregnant * Women of childbearing age who are planning a pregnancy * Women who are breastfeeding * Patients who will not be managed by Cleveland Clinic HPN service * Patients who refuse to use disinfectant wipes daily.

Design outcomes

Primary

MeasureTime frameDescription
Number of Catheter-Related Blood Stream Infections (CRBSI) at 6 Months6 monthsReduction in the number of CRBSI experienced by participants over a six month period (1000 days)

Secondary

MeasureTime frameDescription
Catheter Exchange Rates6 monthsReduction in catheter exchange rates by participants over 1000 days

Countries

United States

Participant flow

Participants by arm

ArmCount
Standard Wipe
Participants will receive a supply of ethanol-based wipes for daily use Ethanol Wipe: Ethanol-based wipe to be used by the participant daily or upon dressing change
29
SQ53 Wipe
Participants will receive a supply of SQ53 wipes for daily use. SQ53 Wipe: SQ53-based wipe to be used by the participant daily or upon dressing change
30
Total59

Baseline characteristics

CharacteristicSQ53 WipeStandard WipeTotal
Age, Continuous51.7 Years
STANDARD_DEVIATION 17.6
52.7 Years
STANDARD_DEVIATION 15
52.2 Years
STANDARD_DEVIATION 16.2
Race/Ethnicity, Customized
African American
2 Participants1 Participants3 Participants
Race/Ethnicity, Customized
Asian or Pacific Islander
0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Caucasian
28 Participants27 Participants55 Participants
Region of Enrollment
United States
30 participants29 participants59 participants
Sex: Female, Male
Female
26 Participants21 Participants47 Participants
Sex: Female, Male
Male
4 Participants8 Participants12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 290 / 30
other
Total, other adverse events
1 / 291 / 30
serious
Total, serious adverse events
0 / 290 / 30

Outcome results

Primary

Number of Catheter-Related Blood Stream Infections (CRBSI) at 6 Months

Reduction in the number of CRBSI experienced by participants over a six month period (1000 days)

Time frame: 6 months

Population: Data analysis was done on all subjects enrolled as well as those that met the protocol defined compliance rates.~Subjects were removed due inability to continue with the protocol (moving to different Home Parenteral Nutrition service or not following treatment guidelines)

ArmMeasureGroupValue (MEAN)
Standard WipeNumber of Catheter-Related Blood Stream Infections (CRBSI) at 6 MonthsIntention to Treat1.98 Infections per 1000 days with catheter
Standard WipeNumber of Catheter-Related Blood Stream Infections (CRBSI) at 6 MonthsMet Protocol Compliance Definitions1.73 Infections per 1000 days with catheter
SQ53 WipeNumber of Catheter-Related Blood Stream Infections (CRBSI) at 6 MonthsIntention to Treat2.09 Infections per 1000 days with catheter
SQ53 WipeNumber of Catheter-Related Blood Stream Infections (CRBSI) at 6 MonthsMet Protocol Compliance Definitions1.02 Infections per 1000 days with catheter
Secondary

Catheter Exchange Rates

Reduction in catheter exchange rates by participants over 1000 days

Time frame: 6 months

Population: Data analysis was done on all subjects enrolled as well as those that met the protocol defined compliance rates.~Subjects were removed due inability to continue with the protocol (moving to different Home Parenteral Nutrition service or not following treatment guidelines)

ArmMeasureGroupValue (MEAN)
Standard WipeCatheter Exchange RatesIntention to Treat1.41 Exchanges per 1000 days with Catheter
Standard WipeCatheter Exchange RatesMet Protocol Compliance Definitions1.26 Exchanges per 1000 days with Catheter
SQ53 WipeCatheter Exchange RatesIntention to Treat1.61 Exchanges per 1000 days with Catheter
SQ53 WipeCatheter Exchange RatesMet Protocol Compliance Definitions0.68 Exchanges per 1000 days with Catheter

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026